Cosmos Health Inc. (COSM) - 10-K Filing Summary
Business Context and Reporting Period
Company: Cosmos Health Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: A vertically integrated global healthcare group operating in pharmaceuticals, nutraceuticals, and healthcare distribution. Key segments include wholesale distribution, pharmaceutical manufacturing (via subsidiary CANA), and proprietary branded products (Sky Premium Life, Mediterranation). The company also operates a drug repurposing AI platform (Cloudscreen) and previously operated a telehealth platform (ZipDoctor), which was discontinued in 2024.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Revenue | $54,426,402 | $53,376,874 |
| Net Loss | $(16,183,018) | $(18,542,654) |
| Gross Profit | $4,311,323 | $4,349,569 |
| Gross Margin | 7.9% | 8.1% |
| Operating Expenses | $19,856,153 | $26,180,786 |
| Net Cash Used in Operating Activities | $(7,717,034) | $(15,635,999) |
| Cash and Cash Equivalents (Ending) | $315,105 | $3,833,195 |
| Working Capital | $(296,193) | $12,285,310 |
| Total Debt (Notes Payable & Lines of Credit) | ~$11.1M | ~$11.2M |
Note: Total debt includes approximately $6.99M in lines of credit and $4.11M in notes payable.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 1.97% to $54.4M, driven by higher wholesale sales (Cosmofarm) and the full-year inclusion of the manufacturing subsidiary CANA (acquired mid-2023).
- Expense Reduction: Total operating expenses decreased 24.16% to $19.9M. This was primarily due to a significant reduction in provisions for expected credit losses ($4.7M in 2024 vs. $11.9M in 2023) and a 70.5% drop in sales and marketing expenses.
- Impairment Charges: The company recorded $291,980 in impairment charges in 2024, related to discontinued branded pharmaceuticals and the write-off of the ZipDoctor telehealth platform. No such charges were recorded in 2023.
- Deemed Dividends: A non-cash deemed dividend of approximately $6.2M was recorded in 2024 related to warrant inducements, increasing the net loss attributable to common stockholders.
- Working Capital Deterioration: Working capital turned negative ($-296k) from a positive $12.3M in 2023, largely due to cash burn from operations and significant allowances for doubtful accounts.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months due to recurring losses, negative working capital, and an accumulated deficit of $114M. Continued operations depend on securing additional financing and executing cost-cutting measures.
- Strategic Outlook: Plans include expanding the Sky Premium Life brand in the UAE (exclusive distribution agreement signed), accessing capital markets via an S-3 registration (eligible August 2025), and pursuing debt refinancing.
- R&D Pipeline: Focus remains on obesity management (CCX0722), CNS cancer, and oncology treatments. The Cloudscreen AI platform is being utilized for drug repurposing.
- Unusual Items:
- Warrant Inducement: In September 2024, the company reduced warrant exercise prices and issued new warrants to raise $4.2M in cash, resulting in significant non-cash deemed dividend expenses.
- Related Party Transactions: Significant transactions with Doc Pharma SA (related to CEO's family), including inventory purchases, license acquisitions, and a royalty agreement for cancer patents.
- Internal Controls: The company disclosed material weaknesses in internal controls, specifically regarding segregation of duties and IT general controls.
Key Facts for Investor Verification
- Liquidity Position: Verify the company's ability to meet short-term obligations given the negative working capital and cash balance of only $315k.
- Debt Covenants: Review terms of the $7M+ in lines of credit and notes payable to ensure compliance with financial covenants and understand upcoming maturity dates.
- Related Party Dependencies: Assess the financial impact and terms of the ongoing royalty and supply agreements with Doc Pharma SA.
- Capital Raising Timeline: Confirm the status of the S-3 registration eligibility and the progress of the UAE distribution deal as primary liquidity drivers.
- Allowance for Doubtful Accounts: Scrutinize the $22.8M allowance for doubtful accounts, which significantly impacts net receivables and working capital.